Article

Circulating Folate Concentrations and Risk of Peripheral Neuropathy and Mortality: A Retrospective Cohort Study in the U.K

Tom Taverner 1,†, Francesca L. Crowe 1,*,†‡, G. Neil Thomas 1, Krishna Gokhale 1, Rasiah Thayakaran 1‡, Krishnarajah Nirantharakumar 1,*,‡ and Yusuf A. Rajabally 2,‡

1 Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Prichatts Road, Birmingham B15 2TT, UK; T.Taverner@bham.ac.uk (T.T.); G.N.Thomas@bham.ac.uk (G.N.T.); K.M.Gokhale@bham.ac.uk (K.G.); R.Thayakaran@bham.ac.uk (R.T.)

2 Aston Brain Centre, Aston University, Aston Triangle, Birmingham B4 7ET, UK; y.rajabally@aston.ac.uk

* Correspondence: F.Crowe@bham.ac.uk (F.L.C.); K.Nirantheran@bham.ac.uk (K.N.);
Tel.: +44-(0)121-4147958 (F.L.C.); +44-(0)121-414 8344 (K.N.); Fax: +44-(0)121-4147878 (F.L.C.);
Tel: Fax: +44-(0)1214147878 (K.N.)

† Joint first authors.
‡ Equal contribution.

Received: 6 September 2019; Accepted: 10 October 2019; Published: 14 October 2019

Abstract: Background: Folate deficiency may increase the risk of peripheral neuropathy but there is a paucity of data from large prospective studies examining this association. Methods: Longitudinal analysis of electronic health records in The Health Improvement Network (THIN), a U.K. primary care database including 594,338 patients aged 18–70 years with a folate measurement and without a history of peripheral neuropathy. Results: After a mean follow-up of 3.71 (standard deviation (SD) = 3.14) years, 1949 patients were diagnosed with peripheral neuropathy and 20,679 patients died. In those <40 years, compared to patients with folate ≥13.6 nmol/L, those with folate <6.8 (deficient) and 6.8–13.5 nmol/L (insufficient) had a hazard ratio (HR) for peripheral neuropathy of 1.83 (95% confidence intervals (CI) = 1.16–2.91) and 1.48 (95% CI = 1.04–2.08), respectively. There was no significant association between folate and peripheral neuropathy among those aged 41–70 years. Compared to patients with folate ≥13.6 nmol/L, folate <6.8 nmol/L was associated with a greater risk of death among all ages. Conclusion: Folate deficiency and insufficiency was associated with a greater risk of peripheral neuropathy among younger patients. This investigation should be replicated in other large datasets and it may be important to monitor peripheral neuropathy incidence after the introduction of mandatory folic acid fortification of flour in the U.K.

Keywords: electronic health records; epidemiology; folate; nutrition; peripheral neuropathy

1. Introduction

Peripheral neuropathy is a term given to indicate a disorder of the peripheral nervous system. It can involve sensory and/or motor fibres, and is relatively common, with an estimated prevalence of 8% in adults older than 55 years [1]. The most common type of peripheral neuropathy is polyneuropathy, with the most common form of polyneuropathy involving the length-dependent axonal part of nerve cells where the process initially involves the axon of the distal portion of the longest nerves with subsequent gradual proximal extension via a “dying back” process. In such cases, the predominant feature is numbness in the lower and upper extremities, paraesthesia and pains, and there is usually a delayed involvement of motor fibres, which causes weakness. As result, polyneuropathy can cause considerable discomfort, pain, functional disability and reduction in the quality of life. The most
common causes of polyneuropathy are diabetes, excessive alcohol consumption and deficiencies in certain vitamins, but about 25% are considered idiopathic [2].

Folate is a water-soluble B vitamin, and in the U.K., good dietary sources are green vegetables, such as broccoli, citrus fruit and foods voluntarily fortified with folic acid, including some breakfast cereals [3]. Deficiency in folate usually results from an insufficient intake but may also be caused by impaired absorption, increased requirements, use of certain medications and chronic alcoholism [4]. Folate deficiency causes neurological manifestations including spina bifida and anencephaly during foetal development [5], and has also been linked with myelopathy [6]. Patients with folate deficiency can develop peripheral neuropathy [7], and folate levels are commonly tested for in the clinical context, although there is little evidence from prospective cohort studies to support this hypothesis. Given the recent decision of the U.K. government to introduce a policy to fortify flour with folic acid [8], it is important to determine whether isolated folate deficiency may have a role in polyneuropathy before this occurs, as folate deficiency is projected to decrease.

In this study we aimed to assess the relationship between folate deficiency and the risk of peripheral neuropathy of an otherwise undetermined aetiology in a large U.K. population younger than 70 years. A secondary objective was to assess the association between serum folate and all-cause mortality.

2. Materials and Methods

2.1. Study Design and Setting

This was a retrospective cohort found in The Health Improvement Network (THIN) primary care database, which contains health records for more than 11 million patients from over 600 general practices (GPs) in the U.K. The distribution of age, sex, prevalence of major medical conditions and mortality rates in the THIN cohort is generalizable to the U.K. population [9]. The database consists of coded information on patient demographics, symptoms and diagnoses, drug prescriptions, consultations, diagnostic tests and their results. The diagnoses in the THIN database are recorded using a hierarchical system called Read codes used to describe a health-related concept in GPs’ records [10]. Collection of data for THIN was approved by the South-East Multicentre Research Ethics Committee in 2003. Approval for the use of THIN data in this analysis was obtained from the Scientific Review Committee in April 2018 (SRC reference 18THIN001).

2.2. Study Population

All data included in this study were from practices that met the acceptable mortality reporting (AMR) and acceptable computer usage (ACU) standards measures of quality assurance for THIN data [11,12]. Adult patients who had a value for circulating concentrations of serum folate from 1 Jan 1990 to 15 May 2017 were included. In order to avoid competition from comorbidities in the older patient population, those 70 years and older were excluded from the analysis. To limit the effects of folate being measured because patients were being investigated for suspected peripheral neuropathy, the main analyses excluded all person-years, diagnoses of peripheral neuropathy and deaths in the first year of follow-up. Some patients had serum folate concentrations measured on multiple occasions but only the first measurement was used for this analysis. A total of 1,052,622 had a measurement of serum folate. Patients were excluded if they had prevalent peripheral neuropathy \((n = 138,903)\), had a value of serum concentrations of folate that was above 68.2 nmol/L or not recorded \((n = 76,854)\), or a missing BMI \((n = 2387)\) or were older than 70 years \((n = 240,140)\) leaving 594,338 patients available for this analysis (Figure 1).
1,052,622 patients with serum folate

913,719 patients with serum folate without peripheral neuropathy

836,865 patients with valid serum folate without peripheral neuropathy

836,865 patients with valid serum folate and BMI without peripheral neuropathy

594,338 included in the analysis

Figure 1. Flow diagram of patients included for an association between serum concentrations of folate and the risk of peripheral neuropathy and mortality.

2.3. Exposures

Folate deficiency was defined as serum folate <6.8 nmol/L, folate insufficiency was defined as serum folate 6.8 to <13.6 and folate sufficiency was defined as serum folate ≥13.6 nmol/L based on World Health Organization (WHO) guidance [13].

2.4. Outcome

Peripheral neuropathy was the primary outcome and was defined using Read codes that included peripheral neuropathy or polyneuropathy but excluded cause-specific peripheral neuropathy, such as diabetes and alcoholism. The secondary outcome for this analysis was death from any cause.

2.5. Statistical Analysis

Person-years of follow-up were calculated from one year after the date of measurement of serum folate concentrations up to whichever came first: diagnosis of peripheral neuropathy, exit from the THIN database (transferred practice or died), the last date practice data was collected or December 31 2017. Cox proportional hazard regression was used to calculate the hazard ratios (HRs) and 95% confidence intervals (CI) of peripheral neuropathy and mortality by categories of serum folate concentrations. As there was a statistically significant folate by age interaction, analyses were conducted separately for the following age categories: <40, 40–55, 56–70 years. All analyses were adjusted for sex; age; fifths of socioeconomic group (based on the Townsend deprivation score), smoking (never, past, current, missing); BMI (<25, 25 to <30, ≥30 kg/m²); vitamin B₁₂ deficiency [13]; use of methotrexate; alcoholism; and chronic liver disease, diabetes, thyroid dysfunction, renal failure, human immunodeficiency virus (HIV) and rheumatoid arthritis. Patients with missing data on covariates were assigned to a separate category for that variable and included in the regression analyses. The p-value for trend of an association between serum concentrations of folate and risk of peripheral neuropathy and mortality was taken from the Cox proportional hazard coefficients. It is possible that undiagnosed
A disease may cause people to become unwell, which can result in some individuals changing their diet, and may lead to reverse causation bias whereby low serum folate are a consequence, rather than a cause of the disease. To minimise this type of bias, analyses for peripheral neuropathy and mortality were repeated by censoring an additional two years of follow-up.

All statistical analyses were performed using R software [14]. Two-sided \(p\)-values <0.05 were considered statistically significant.

3. Results

There were 390,675 women and 203,663 men with a measurement of serum folate concentration included in this analysis. Table 1 shows the characteristics of the patients and details of their follow-up according to the categories of baseline serum concentrations of folate. Among all patients, the mean serum folate concentration was 18.7 (SD = 10.7) nmol/L. Across increasing categories of serum folate, the percentage who were women increased as did the average age. Those with a higher serum folate were more likely to be from the least deprived areas, have a BMI in the normal range and were less likely to be current smokers. Across the increasing categories of folate, serum concentrations of vitamin B\(_{12}\) also increased.

Table 1. Characteristics of THIN patients according to categories of serum concentrations of folate.

| Serum Concentrations of Folate (nmol/L) | <6.8 | 6.8–13.5 | ≥ 13.6 | \(p\)-Value |
|-----------------|------|---------|-------|------------|
| \(n\)            | 38,574 | 187,550 | 368,214 |           |
| Age (years), mean (SD) | 45.1 (14.2) | 46.1 (14.2) | 48.9 (13.5) | <0.001 |
| BMI (kg/m\(^2\)), mean (SD) | 28.0 (7.4) | 27.8 (6.7) | 26.8 (5.7) | <0.001 |
| Men, \(n\) (%)        | 13,451 (34.9%) | 66,400 (35.4%) | 123,812 (33.6%) | <0.001 |
| Age group, \(n\) (%)   | <0.001 | <0.001 | <0.001 |           |
| 18–40 years          | 14,696 (38.1%) | 66,681 (35.6%) | 104,970 (28.5%) |           |
| 41–55 years          | 13,378 (34.7%) | 65,946 (35.2%) | 129,547 (35.2%) | <0.001 |
| 56-70 years          | 10,500 (27.2%) | 54,923 (29.3%) | 133,697 (36.3%) |           |
| Townsend deprivation index | <0.001 | <0.001 |           |           |
| 1 (least deprived)   | 4630 (12.8%) | 30,899 (17.5%) | 81,690 (23.5%) |       |
| 2                   | 5073 (14.0%) | 29,601 (16.8%) | 69,308 (19.9%) |       |
| 3                   | 6747 (18.6%) | 34,082 (19.3%) | 66,832 (19.2%) |       |
| 4                   | 7897 (21.8%) | 34,503 (19.5%) | 55,031 (15.8%) | <0.001 |
| 5 (most deprived)    | 8104 (22.4%) | 28,824 (16.3%) | 36,836 (10.6%) |       |
| Not known            | 3535 (9.8%) | 18,269 (10.3%) | 37,286 (10.7%) |       |
| Ethnicity, \(n\) (%) | <0.001 | <0.001 |           |           |
| Asian or Asian British | 549 (1.4%) | 4872 (2.6%) | 10,946 (3.0%) |       |
| Black or black British | 329 (0.9%) | 2674 (1.4%) | 6122 (1.7%) |       |
| White                | 13,521 (35.1%) | 69,216 (36.9%) | 133,451 (36.2%) | <0.001 |
| Mixed                | 92 (0.2%) | 677 (0.4%) | 1381 (0.4%) |       |
| Other                | 127 (0.3%) | 1030 (0.5%) | 3487 (0.9%) |       |
| Not known            | 23,956 (62.1%) | 109,081 (58.2%) | 212,827 (57.8%) |       |
| Smoking              | <0.001 | <0.001 | <0.001 |           |
| Non-smokers          | 13,043 (33.8%) | 89,818 (47.9%) | 220,822 (60.0%) |       |
| Former smokers       | 7,081 (18.4%) | 40,208 (21.4%) | 85,197 (23.1%) |       |
| Current smokers      | 18,101 (46.9%) | 56,062 (29.9%) | 59,665 (16.2%) | <0.001 |
| Not known            | 349 (0.9%) | 1462 (0.8%) | 2530 (0.7%) |       |
| Follow-up            |           |           |           |           |
| Person-years of follow-up | 684,809 | 576,934 | 1,353,773 |       |
| New cases of peripheral neuropathy | 204 | 598 | 1147 |       |
| Deaths               | 10,675 | 2842 | 7162 |       |

Abbreviations: SD—standard deviation; BMI—body mass index; THIN—The Health Improvement Network.
After a mean follow-up of 3.7 (SD = 3.1) years, there were 1949 patients diagnosed with peripheral neuropathy (947 women and 1002 men) and 20,679 patients died (9695 women and 10,984 men). The incidence of peripheral neuropathy was higher in men (0.49%) than in women (0.24%).

Figure 2 shows the unadjusted cumulative hazard of peripheral neuropathy for the three age groups according to serum concentrations of folate.

![Cumulative event curves for peripheral neuropathy](image)

**Figure 2.** Cumulative event curves for peripheral neuropathy according to serum folate concentrations and age, using 95% Kaplan-Meier confidence interval (CI). Time in days (d).

After adjusting for age, sex and other confounding variables, there was an inverse relation between serum folate concentrations and peripheral neuropathy among those <40 years of age. The adjusted hazard ratios with baseline folate >13.6 nmol/L set as a reference within each age group are shown in Table 2. There was a dose-response association between serum folate and the risk of peripheral neuropathy in participants aged 18–40 years old; those with low-medium folate (6.8–13.6 nmol/L) and low folate (<6.8 nmol/L) had a HR 1.83 (95% CI = 1.16–2.91) and 1.48 (95% CI = 1.04–2.08), respectively, greater hazard of peripheral neuropathy compared to patients with normal serum folate. The strength of the association between serum folate and hazards of peripheral neuropathy was not significant among participants aged 41–55 years of age (p-trend = 0.35) and aged 56–70 years (p-trend = 0.31).

**Table 2.** Hazard ratios (95% CI (confidence intervals)) of peripheral neuropathy and mortality according to categories of serum folate concentrations and age group.

| Serum Concentrations of Folate (nmol/L) | <6.8 (1.16–2.91) | 6.8–13.5 (1.04–2.08) | >13.6 (1.00 (ref)) | p for Trend |
|--------------------------------------|-------------------|----------------------|---------------|-------------|
| Peripheral neuropathy                |                   |                      |               |             |
| 18–40 years                          | 1.83              | 1.48                 | 1.00 (ref)    | 0.0043      |
| 41–55 years                          | 1.11 (0.85–1.45)  | 1.06 (0.89–1.27)     | 1.00 (ref)    | 0.35        |
| 56–70 years                          | 0.91 (0.71–1.17)  | 0.94 (0.82–1.07)     | 1.00 (ref)    | 0.31        |
| Mortality                            |                   |                      |               |             |
| 18–40 years                          | 1.55 (1.26–1.90)  | 1.07 (0.91–1.24)     | 1.00 (ref)    | 0.0002      |
| 41–55 years                          | 1.66 (1.51–1.83)  | 1.23 (1.15–1.32)     | 1.00 (ref)    | <0.0001     |
| 56–70 years                          | 1.48 (1.40–1.57)  | 1.30 (1.25–1.34)     | 1.00 (ref)    | <0.0001     |

1 Adjusted for sex, age, socioeconomic group, smoking, BMI, vitamin B12 deficiency, use of methotrexate, alcoholism, chronic liver disease, diabetes, thyroid dysfunction, renal failure, human immunodeficiency virus (HIV) and rheumatoid arthritis. 2 Test for linear trend.

The inverse association between serum folate concentrations and the risk of mortality was evident across the three age groups where HR in the lowest folate category compared with the highest folate category was 1.55 (95% CI = 1.26–1.90) in those aged 18–40 years, 1.66 (95% CI = 1.51–1.83) in those aged 41–55 years and 1.48 (95% CI = 1.40–1.57) in those aged 56–70 years.

All analyses were repeated after censoring an additional two years from the index data and the results are shown in Table 3. The inverse association between lowest folate and peripheral neuropathy at
ages 18–40 years was attenuated (HR = 1.49; 95% CI = 0.90–2.46) and folate 6.8–13.6 nmol/L (HR = 1.39; 95% CI = 0.97–1.98, p-trend = 0.05). Censoring of an additional two years of follow-up made little difference to the association of serum folate and hazards of mortality.

Table 3. Hazard ratios (95% CI) of peripheral neuropathy and mortality according to the categories of serum folate concentrations and age group after censoring an additional two years of follow-up.\(^1,2\)

| Serum Concentrations of Folate (nmol/L) | <6.8 | 6.8–13.5 | ≥13.6 | p for Trend \(^3\) |
|----------------------------------------|------|----------|-------|-------------------|
| Peripheral neuropathy                  |      |          |       |                   |
| 18–40 years                            | 1.49 (0.90–2.47) | 1.41 (0.99–2.01) | 1.00 (ref) | 0.05              |
| 41–55 years                            | 1.16 (0.88–1.53) | 1.12 (0.93–1.34) | 1.00 (ref) | 0.187             |
| 56–70 years                            | 0.94 (0.73–1.22) | 0.97 (0.85–1.12) | 1.00 (ref) | 0.588             |
| Mortality                              |      |          |       |                   |
| 18–40 years                            | 1.53 (1.19–1.97) | 1.07 (0.88–1.30) | 1.00 (ref) | 0.0032            |
| 41–55 years                            | 1.65 (1.47–1.86) | 1.31 (1.20–1.42) | 1.00 (ref) | <0.0001           |
| 56–70 years                            | 1.45 (1.35–1.55) | 1.30 (1.24–1.36) | 1.00 (ref) | <0.0001           |

\(^1\) Adjusted for sex, age, socioeconomic group, smoking, BMI, vitamin B\(_{12}\) deficiency, use of methotrexate, alcoholism, chronic liver disease, diabetes, thyroid dysfunction, renal failure, human immunodeficiency virus (HIV) and rheumatoid arthritis. \(^2\) Includes 1792 cases of peripheral neuropathy and 13,257 deaths. \(^3\) Test for linear trend.

The correlation between vitamin B\(_{12}\) and folate concentrations as measured using Pearson’s correlation was \(r = 0.24\). There was no overall association between serum vitamin B\(_{12}\) concentrations and the risk of peripheral neuropathy.

4. Discussion

For the patients 40 years and younger, circulating folate concentrations were inversely associated with the risk of developing peripheral neuropathy in a dose-dependent manner. There was also a significant inverse association between serum folate and mortality across all age groups.

Only a few observational studies have examined the relationship between serum folate and the risk of peripheral neuropathy; results from one small cross-sectional study showed that in patients with Parkinson’s disease there was an inverse association between serum folate and the risk of peripheral neuropathy that was independent of age [15]. The results from this study are difficult to interpret since serum folate concentrations were measured at around the time of disease diagnosis, and patients may have changed their diet because of early symptoms, before the formal diagnosis of peripheral neuropathy. There have been several small case-series reports of patients with neuropathy and folate deficiency [7,16]. In the first such study, the symptoms of 8 out of 10 patients (80%) with neuropathy and isolated folate deficiency were either reversed, or they responded to folate treatment [7]. Yukawa et al. [17] showed that the neurological symptoms improved after folic acid supplementation in 24 out of 36 (67%) patients with concomitant folate deficiency and neuropathy. Whereas, Koike et al. [16] reported that only 5 out of 18 (28%) folate deficient neuropathy patients had some improvements in their symptoms after supplementing with folic acid. While the results from these studies may appear compelling, the lack of a comparison group makes it difficult to establish whether the folate treatment caused the improvement in symptoms or symptoms may have naturally resolved over time. Results from a systematic review of randomised or quasi-randomised trials showed that B vitamins were not effective at treating peripheral neuropathy in patients with diabetes or alcoholism but none of the trials’ supplements included folic acid [18]. In the absence of large randomised controlled trial evidence, the association between serum folate and peripheral neuropathy should be examined in other large longitudinal studies. It is also possible that the imminent introduction of folic acid fortification of flour in the U.K. [8] will act as a natural experiment to evaluate not only the effect on the incidence of neural tube defects, but also the effect on the incidence of peripheral neuropathy. It will be of particular importance to examine whether any change in serum folate and incidence of peripheral neuropathy
Peripheral neuropathy is much more common among patients with vitamin B₁₂ deficiency because of the role that vitamin B₁₂ has as a co-enzyme in the conversion of homocysteine to methionine, a precursor to S-adenosyl methionine (SAM), which is important for myelination of nerve cells [19]. As nerve cells may have some ability to accumulate folate, the risk of neuropathy in those with folate deficiency is meant to be much rarer than that of vitamin B₁₂ deficiency [20]. Nevertheless, because of the essential role of folate in the methylation of homocysteine to methionine [19], together with evidence from this and other studies, deficiency in folate may pose a much greater risk for the development of peripheral neuropathy, particularly among younger people, than previously thought. These results suggest that clinicians should continue to measure serum folate in patients suspected of having peripheral neuropathy.

The inverse association between serum folate and risk of all-cause mortality has also been reported in one other large cohort study conducted in the USA where flour has been mandatorily fortified with folic acid since 2002 [21]. Despite the strong association between serum folate and mortality in our study, an individual patient meta-analysis of randomised controlled trials showed that the risk of dying among participants allocated to folic acid supplementation (either alone or in combination with vitamin B₆ and/or vitamin B₁₂) was not significantly different from the control group [22]. This is further supported by the results from a large trial in China of folic acid supplementation that was not included in the meta-analysis [23]. While the inverse association between serum folate and mortality in this analysis was quite strong, it is possible that it is the result of residual confounding or confounding by unmeasured variables [24].

This study has some limitations. From the patients’ records, we were not able to determine the method used to measure serum folate concentrations, which is important as methods, such as folate binding assays, produce systematically lower folate results than the microbiological assay or the gold standard liquid chromatography coupled to tandem mass spectrometry [25]. However, the mean serum folate concentration from this patient population of 18.7 nmol/L is only slightly lower than that of men and women age 19 to 64 years from the 2008–09–2011/12 National Diet and Nutrition Survey of 19.8 nmol/L [26]. This study may be vulnerable to bias since tests for folate may be requested in response to particular symptoms, such as distal paraesthesiae or pain (possibly suggestive of neuropathy), despite the absence of an established neuropathy diagnosis at the time of testing. To overcome this source of bias, the entire first year of follow-up was censored in the main analysis. The neuropathy subtype was also not considered here, and although sensory axonal neuropathies are the most commonly observed, there was no detailed clinical data available. The current analysis used only the first measurement of serum folate and this might not reflect long-term or usual values. Several studies of serum folate in blood samples taken one to four years apart have reported intra-class correlations between 0.5 and 0.6 [27–29]. This could mean that the associations of serum folate and peripheral neuropathy risk could be stronger than those reported here. Finally, the population studied has a larger proportion of women than the general U.K. population, potentially limiting the generalisability of these findings.

In conclusion, our results suggest that folate deficiency is a risk factor for neuropathy in patients younger than 40 years. Importantly, the risk of peripheral neuropathy increased as serum folate decreased, and even insufficient serum folate of 6.8 to 13.5 nmol/L appeared to be important. These associations warrant further investigation in other large electronic health datasets. Moreover, future surveillance of peripheral neuropathy in the U.K. after the introduction of folic acid fortification of flour may help to understand whether improving serum folate concentrations in the population also leads to a change in the incidence of peripheral neuropathy across the different age groups.
Author Contributions: Conceptualization, Y.A.R. and K.N.; Data Curation, K.G.; Formal Analysis, T.T. and R.T.; Writing-Original Draft Preparation, T.T. and F.L.C.; Writing-Review & Editing, T.T., F.L.C., G.N.T., K.G., R.T., K.N. and Y.A.R.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Martyn, C.N.; Hughes, R.A.C. Epidemiology of Peripheral Neuropathy. J. Neurol. Neurosurg. Psychiatry 1997, 62, 310–318. [CrossRef] [PubMed]
2. England, J.D.; Asbury, A.K. Peripheral Neuropathy. Lancet 2004, 363, 2151–2161. [CrossRef]
3. Roberts, C.; Steer, T.; Maplethorpe, N.; Cox, L.; Meadows, S.; Nicholson, S.; Page, P.; Swan, G. National Diet and Nutrition Survey Results from Years 7 and 8 (Combined) of the Rolling Programme (2014 to 2015 and 2015 to 2016); Public Health England: London, UK, 2018.
4. Allen, L.H. Causes of Vitamin B12 and Folate Deficiency. Food Nutr. Bull. 2008, 29, S20–S34. [CrossRef] [PubMed]
5. Daly, L.E.; Kirke, P.N.; Molloy, A.; Weir, D.G.; Scott, J.M. Folate Levels and Neural Tube Defects: Implications for Prevention. JAMA 1995, 274, 1698–1702. [CrossRef] [PubMed]
6. Reynolds, E.H. The Neurology of Folic Acid Deficiency. Handb. Clin. Neurol. 2014, 120, 927–943. [PubMed]
7. Manzoor, M. Folate-Responsive Neuropathy: Report of 10 Cases. Brit. Med. J. 1976, 1, 1176–1178. [CrossRef] [PubMed]
8. Limb, M. Flour to be Fortified with Folic Acid within Weeks, Say Reports. BMJ 2018, 363, k4348. [CrossRef]
9. Blak, B.T.; Thompson, M.; Dattani, H.; Bourke, A. Generalisability of the Health Improvement Network (THIN) Database: Demographics, Chronic Disease Prevalence and Mortality Rates. Inf. Prim. Care 2011, 19, 251–255. [CrossRef]
10. Booth, N. What are the Read Codes? Heal. Libr. Rev. 1994, 11, 177–182.
11. Maguire, A.; Blak, B.T.; Thompson, M. The Importance of Defining Periods of Complete Mortality Reporting for Research using Automated Data from Primary Care. Pharmacoepidemiol. Drug Saf. 2009, 18, 76–83. [CrossRef]
12. Horsfall, L.; Walters, K.; Petersen, I. Identifying Periods of Acceptable Computer Usage in Primary Care Research Databases. Pharmacoepidemiol. Drug Saf. 2013, 22, 64–69. [CrossRef] [PubMed]
13. De Benoist, B. Conclusions of a WHO Technical Consultation on Folate and Vitamin B12 Deficiencies. Food Nutr. Bull. 2008, 29, S238–S244. [CrossRef] [PubMed]
14. Team, R.C. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2018.
15. Rajabally, Y.A.; Martey, J. Levodopa, Vitamins, Ageing and the Neuropathy of Parkinson’s Disease. J. Neurol. 2013, 260, 2844–2848. [CrossRef] [PubMed]
16. Koike, H.; Takahashi, M.; Ohyama, K.; Hashimoto, R.; Kawagashira, Y.; Iijima, M.; Katsuno, M.; Doi, H.; Tanaka, F.; Sobue, G. Clinicopathologic Features of Folate-Deficiency Neuropathy. Neurology 2015, 84, 1026–1033. [CrossRef] [PubMed]
17. Yukawa, M.; Naka, H.; Murata, Y.; Katayama, S.; Kohriyama, T.; Mimori, Y.; Nakamura, S. Folic Acid-Responsive Neurological Diseases in Japan. J. Nutr. Sci. Vitaminol. 2001, 47, 181–187. [CrossRef]
18. Ang, C.D.; Alviar, M.J.M.; Dans, A.L.; Bautista-Velez, G.G.P.; Villaruz-Sulit, M.V.C.; Tan, J.J.; Co, H.U.; Bautista, M.R.M.; Roxas, A.A. Vitamin B for Treating Peripheral Neuropathy. Cochrane Database Syst. Rev. 2008, 16, CD004573. [CrossRef]
19. Selhub, J. Folate, Vitamin B12 and Vitamin B6 and One Carbon Metabolism. J. Nutr. Health Aging 2002, 6, 39–42.
20. Gibson, R.S. Assessment of folate and B12 status. In Principles of Nutritional Assessment, 2nd ed.; Oxford University Press Inc.: New York, NY, USA, 2005; pp. 595–640.
21. Peng, Y.; Dong, B.; Wang, Z. Serum Folate Concentrations and all-Cause, Cardiovascular Disease and Cancer Mortality: A Cohort Study Based on 1999–2010 National Health and Nutrition Examination Survey (NHANES). Int. J. Cardiol. 2016, 219, 136–142. [CrossRef]
22. Clarke, R.; Halsey, J.; Lewington, S.; Lonn, E.; Armitage, J.; Manson, J.E.; Bønaa, K.H.; Spence, J.D.; Nygård, O.; Jamison, R.; et al. Effects of Lowering Homocysteine Levels with B Vitamins on Cardiovascular Disease, Cancer, and Cause-Specific Mortality: Meta-Analysis of 8 Randomized Trials Involving 37,485 Individuals. *Arch. Intern. Med.* 2010, 170, 1622–1631.

23. Huo, Y.; Li, J.; Qin, X.; Huang, Y.; Wang, X.; Gottesman, R.F.; Tang, G.; Wang, B.; Chen, D.; He, M.; et al. Efficacy of Folic Acid Therapy in Primary Prevention of Stroke among Adults with Hypertension in China: The CSPPT Randomized Clinical Trial. *JAMA* 2015, 313, 1325–1335. [CrossRef]

24. Freedman, L.S.; Schatzkin, A.; Midthune, D.; Kipnis, V. Dealing with Dietary Measurement Error in Nutritional Cohort Studies. *J. Natl. Cancer Inst.* 2011, 103, 1086–1092. [CrossRef] [PubMed]

25. Fazili, Z.; Pfeiffer, C.M.; Zhang, M. Comparison of Serum Folate Species Analyzed by LC-MS/MS with Total Folate Measured by Microbiologic Assay and Bio-Rad Radioassay. *Clin. Chem.* 2007, 53, 781–784. [CrossRef] [PubMed]

26. Bates, B.; Lennox, A.; Prentice, A.; Bates, C.; Swan, G. *National Diet and Nutrition Survey; Headline Results from Years 1, 2 and 3 (Combined) of the Rolling Programme (2008/2009–2010/11)*; Public Health England: London, UK, 2012.

27. Cope, E.L.; Shrubsole, M.J.; Cohen, S.S.; Cai, Q.; Wu, J.; Ueland, P.M.; Midttun, O.; Sonderman, J.S.; Blot, W.J.; Signorello, L.B. Intraindividual Variation in One-Carbon Metabolism Plasma Biomarkers. *Cancer Epidemiol. Biomarkers Prev.* 2013, 22, 1894–1899. [CrossRef] [PubMed]

28. Leenders, M.; Ros, M.M.; Sluijs, I.; Boshuizen, H.C.; van Gils, C.H.; Jansen, E.H.; Bueno-de-Mesquita, H.B. Reliability of Selected Antioxidants and Compounds Involved in One-Carbon Metabolism in Two Dutch Cohorts. *Nutr. Cancer* 2015, 65, 17–24. [CrossRef] [PubMed]

29. Midttun, O.; Townsend, M.K.; Nygard, O.; Tworoger, S.S.; Brennan, P.; Johansson, M.; Ueland, P.M. Most Blood Biomarkers Related to Vitamin Status, One-Carbon Metabolism, and the Kynurenine Pathway show Adequate Preanalytical Stability and within-Person Reproducibility to Allow Assessment of Exposure Or Nutritional Status in Healthy Women and Cardiovascular Patients. *J. Nutr.* 2014, 144, 784–790. [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).